Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer’s disease trial
Late-stage trial in Alzheimer&…
Late-stage trial in Alzheimer&…
BEIJING, Dec. 9, 2024 /PRNewsw…
Third-generation member of Tha…
Accelerating global expansion …
More Travel Protection Product…
OSLO, Norway, Dec. 9, 2024 /PR…
TAIPEI, Dec. 9, 2024 /PRNewswi…
SHENZHEN, China, Dec. 9, 2024 …